Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Serum Laboratory Studies, Stool Test, Breath Test01:30

Serum Laboratory Studies, Stool Test, Breath Test

343
Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...
343

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular Nonendoscopic Tests for the Early Detection of Esophageal Squamous Carcinoma and High-Grade Dysplasia: Promising Progress.

The American journal of gastroenterology·2026
Same author

Enhanced Molecular Staging of Pancreatic Cancer Using Methylated DNA Markers in Peritoneal Lavage Fluid.

Journal of surgical oncology·2026
Same author

A multi-analyte cfDNA-based blood test for early detection of hepatocellular carcinoma.

Journal of hepatology·2026
Same author

Optimization of methylated DNA markers to rule out endometrial cancer in patients with abnormal uterine bleeding.

Gynecologic oncology·2026
Same author

Clinical characteristics and outcomes of appendiceal neoplasms in inflammatory bowel disease: A tertiary care center experience.

Clinics and research in hepatology and gastroenterology·2026
Same author

Diagnostic and Prognostic Biomarkers for Barrett's Esophagus.

Gastroenterology clinics of North America·2026

Related Experiment Video

Updated: Jul 1, 2025

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
07:35

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Published on: June 8, 2020

6.9K

Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening.

Thomas F Imperiale1, Kyle Porter1, Julia Zella1

  • 1From the Indiana University School of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, and Regenstrief Institute, Indianapolis (T.F.I.); Exact Sciences, Madison, WI (K.P., J.Z., Z.D.G., M.C.O., S.S., J.G., P.J.L.); Boston Biostatistics Research Foundation, Framingham, MA (P.T.L.); Louisiana Research Center, Shreveport (H.A.); Great Lakes Gastroenterology Research, Mentor, OH (D.B.); Southwest Gastroenterology, Oak Lawn, IL (C.B.); and the Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN (J.B.K.).

The New England Journal of Medicine
|March 13, 2024
PubMed
Summary
This summary is machine-generated.

A new multitarget stool DNA test shows higher sensitivity for detecting colorectal cancer and precancerous lesions compared to fecal immunochemical tests (FIT). However, this advanced screening tool demonstrated lower specificity for advanced neoplasia.

More Related Videos

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
15:17

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing

Published on: September 25, 2011

14.0K
Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

6.5K

Related Experiment Videos

Last Updated: Jul 1, 2025

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
07:35

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Published on: June 8, 2020

6.9K
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
15:17

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing

Published on: September 25, 2011

14.0K
Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

6.5K

Area of Science:

  • Gastroenterology
  • Oncology
  • Molecular Diagnostics

Background:

  • Colorectal cancer (CRC) screening aims to detect cancer and precancerous lesions early.
  • Next-generation multitarget stool DNA tests combine molecular markers and hemoglobin detection.
  • Improving screening performance, particularly specificity, is a key objective.

Purpose of the Study:

  • To evaluate the performance of a next-generation multitarget stool DNA test.
  • To compare its sensitivity and specificity against a fecal immunochemical test (FIT).
  • To assess its utility in asymptomatic adults aged 40+ undergoing screening colonoscopy.

Main Methods:

  • Prospective study involving 20,176 asymptomatic adults aged 40 years or older.
  • Evaluation of a multitarget stool DNA test assessing DNA markers and hemoglobin.
  • Primary outcomes: sensitivity for CRC, specificity for advanced neoplasia; Secondary outcomes: sensitivity for advanced precancerous lesions, specificity for negative colonoscopy.

Main Results:

  • The multitarget stool DNA test achieved 93.9% sensitivity for CRC and 43.4% for advanced precancerous lesions.
  • Specificity for advanced neoplasia was 90.6%, and for negative colonoscopy was 92.7%.
  • Compared to FIT, the new test showed superior sensitivity for CRC (93.9% vs 67.3%) and advanced precancerous lesions (43.4% vs 23.3%), but lower specificity for advanced neoplasia (90.6% vs 94.8%).

Conclusions:

  • The next-generation multitarget stool DNA test offers enhanced sensitivity for colorectal cancer and advanced precancerous lesions over FIT.
  • The trade-off for higher sensitivity is a reduction in specificity for advanced neoplasia.
  • The test is a promising tool for CRC screening, though its specificity profile requires consideration.